Abstract
The intersection of cannabis use disorder (CUD) and critical illness outcomes in cancer patients represents a burgeoning area of research, particularly as cannabis legalization and therapeutic applications expand globally. Adjusted analyses of a retrospective cohort study by Sager et al revealed significantly lower odds of all-cause mortality (adjusted odds ratio (aOR) = 0.83) and respiratory failure (aOR = 0.8) in CUD-positive patients, alongside elevated hospitalization costs. These findings suggest the potential immunomodulatory and organ-protective effects of cannabinoids on sepsis. Future research must prioritize mechanistic studies, prospective clinical trials, and socioeconomic interventions to translate these findings into actionable clinical strategies, to align policy recommendations with guidelines, including those presented by the National Comprehensive Cancer Network.